AstraZeneca PLC Release: BYDUREON® Pen, A Treatment Option For Adults With Type 2 Diabetes, Now Available In Pharmacies

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE:AZN) today announced that once-weekly BYDUREON® (exenatide extended-release for injectable suspension) Pen 2 mg, a prescription medicine, is now available in pharmacies across the United States. BYDUREON is approved by the U.S. Food and Drug Administration as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. BYDUREON is not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise and should not be used for treatment of patients with type 1 diabetes or diabetic ketoacidosis. BYDUREON is not a substitute for insulin. The concurrent use of BYDUREON with insulin has not been studied and is not recommended. BYDUREON and BYETTA® (exenatide) injection contain the same active ingredient and should not be used together.

Help employers find you! Check out all the jobs and post your resume.